MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN
The review outlines the main mechanisms of protective estrogen effects on cardiovascular system and the role of estrogen deficiency in cardiovascular disease (CVD) development. The position of the International Menopause Society (2009) on CVD in women is summarized. The importance of non-pharmaceuti...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2011-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1180 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410238071963648 |
|---|---|
| author | S. N. Tolstov I. A. Salov V. B. Mychka M. Yu. Kirillova N. A. Voychenko I. V. Kuznetsova |
| author_facet | S. N. Tolstov I. A. Salov V. B. Mychka M. Yu. Kirillova N. A. Voychenko I. V. Kuznetsova |
| author_sort | S. N. Tolstov |
| collection | DOAJ |
| description | The review outlines the main mechanisms of protective estrogen effects on cardiovascular system and the role of estrogen deficiency in cardiovascular disease (CVD) development. The position of the International Menopause Society (2009) on CVD in women is summarized. The importance of non-pharmaceutical measures in lifestyle modification and CVD risk factor (RF) management is discussed. The main principles of pharmaceutical treatment in premenopausal women are presented, together with the clinical evidence on mildronate in CVD prevention. The specific features of antihypertensive therapy in menopausal women are discussed. The authors justify the use of an angiotensin II receptor antagonist losartan as a first-choice medication for the management of arterial hypertension (AH) and metabolic disturbances. The role of lipid-lowering and glucose-lowering therapy is also demonstrated. Mutual efforts of cardiologists and gynecologists, together with active monitoring, are important components of RF management and primary CVD prevention in women. |
| format | Article |
| id | doaj-art-84f1320cce65436d8bf64b5bfa3d6247 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2011-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-84f1320cce65436d8bf64b5bfa3d62472025-08-20T03:35:11Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202011-12-010698104984MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMENS. N. Tolstov0I. A. Salov1V. B. Mychka2M. Yu. Kirillova3N. A. Voychenko4I. V. Kuznetsova5ГОУ ВПО Саратовский ГМУ Росздрава, СаратовГОУ ВПО Саратовский ГМУ Росздрава, СаратовФГУ Российский кардиологический научно – производственный комплекс Росмедтехнологий, Институт клинической кардиологии им. А. Л. Мясникова – отдел системных гипертензий, МоскваФГУ Российский кардиологический научно – производственный комплекс Росмедтехнологий, Институт клинической кардиологии им. А. Л. Мясникова – отдел системных гипертензий, МоскваПервый Московский государственный медицинский университет имени И. М. Сеченова, МоскваГОУ ДПО Российская медицинская академия последипломного образования Росздрава, МоскваThe review outlines the main mechanisms of protective estrogen effects on cardiovascular system and the role of estrogen deficiency in cardiovascular disease (CVD) development. The position of the International Menopause Society (2009) on CVD in women is summarized. The importance of non-pharmaceutical measures in lifestyle modification and CVD risk factor (RF) management is discussed. The main principles of pharmaceutical treatment in premenopausal women are presented, together with the clinical evidence on mildronate in CVD prevention. The specific features of antihypertensive therapy in menopausal women are discussed. The authors justify the use of an angiotensin II receptor antagonist losartan as a first-choice medication for the management of arterial hypertension (AH) and metabolic disturbances. The role of lipid-lowering and glucose-lowering therapy is also demonstrated. Mutual efforts of cardiologists and gynecologists, together with active monitoring, are important components of RF management and primary CVD prevention in women.https://russjcardiol.elpub.ru/jour/article/view/1180menopauserisk factorsnon-pharmaceutical measuresmildronateantihypertensive therapylosartan |
| spellingShingle | S. N. Tolstov I. A. Salov V. B. Mychka M. Yu. Kirillova N. A. Voychenko I. V. Kuznetsova MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN Российский кардиологический журнал menopause risk factors non-pharmaceutical measures mildronate antihypertensive therapy losartan |
| title | MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN |
| title_full | MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN |
| title_fullStr | MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN |
| title_full_unstemmed | MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN |
| title_short | MAIN THERAPEUTIC PRINCIPLES IN PREMENOPAUSAL WOMEN |
| title_sort | main therapeutic principles in premenopausal women |
| topic | menopause risk factors non-pharmaceutical measures mildronate antihypertensive therapy losartan |
| url | https://russjcardiol.elpub.ru/jour/article/view/1180 |
| work_keys_str_mv | AT sntolstov maintherapeuticprinciplesinpremenopausalwomen AT iasalov maintherapeuticprinciplesinpremenopausalwomen AT vbmychka maintherapeuticprinciplesinpremenopausalwomen AT myukirillova maintherapeuticprinciplesinpremenopausalwomen AT navoychenko maintherapeuticprinciplesinpremenopausalwomen AT ivkuznetsova maintherapeuticprinciplesinpremenopausalwomen |